Form 4: Director Lazar Acquires $3M in Mainz Biomed Preferred Shares

Mainz Biomed N.V. Director David E. Lazar acquired $3 million in preferred shares, with an additional $3 million pending, contingent on significant stockholder approvals including a reverse stock split and board changes.

Summary

• David E. Lazar, a Director and 10% owner of Mainz Biomed N.V., acquired 3,000,000 Series A, B, and C Preferred Shares on February 13, 2026, for $1.00 per share, totaling $3,000,000.
• An additional 2,000,000 Series D and E Preferred Shares will be acquired at a subsequent closing for $1.50 per share, totaling $3,000,000, bringing the total potential investment to $6,000,000.
• The conversion of these Preferred Shares into ordinary shares is contingent upon 'Stockholder Approval'.
• Stockholder Approval requires an increase in authorized ordinary shares to at least 900,000,000, approval of the conversion, a reverse stock split, and the election of Lazar and his designees to the Board of Directors.
• Upon approval, Series A, B, and C Preferred Shares will convert into 9 ordinary shares each, and Series D and E Preferred Shares will convert into 225 ordinary shares each, subject to certain ownership limitations.
• The Preferred Shares are perpetual and have no expiration date.
• Currently, no ordinary shares are beneficially owned by Lazar as conversion is pending.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a necessary capital injection for Mainz Biomed N.V., but the terms, particularly the contingent nature of conversion, the requirement for a reverse stock split, and the potential for significant dilution, indicate underlying challenges and create substantial uncertainty for existing shareholders.

Positives

• Significant capital injection of $3,000,000 immediately, with a potential additional $3,000,000, totaling $6,000,000, providing crucial funding for the company.
• A Director and 10% owner is increasing his stake, signaling confidence in the company's future.
• The preferred shares are perpetual, providing long-term capital without a fixed maturity date.

Negatives

• Conversion of preferred shares into ordinary shares is subject to multiple significant conditions, including stockholder approval for a reverse stock split and an increase in authorized shares, which could be dilutive.
• The requirement for a reverse stock split often indicates a low share price and potential delisting risk from Nasdaq.
• The substantial increase in authorized ordinary shares (to 900,000,000) and the high conversion ratio for Series D/E shares (225 ordinary shares per preferred share) suggest significant potential dilution for existing shareholders upon conversion.
• The election of the Reporting Person and his designees to the Board of Directors as a condition for conversion could indicate a shift in control or influence.

Risks

• **Dilution Risk**: Significant potential dilution for existing ordinary shareholders if the preferred shares convert, especially given the high conversion ratio for Series D/E shares and the proposed increase in authorized shares to 900,000,000.
• **Stockholder Approval Risk**: The conversion is contingent on multiple stockholder approvals, including a reverse stock split and board changes, which may not be obtained, leaving the preferred shares unconverted.
• **Reverse Stock Split Risk**: A reverse stock split, while potentially necessary for Nasdaq compliance, can sometimes be viewed negatively by the market and may not guarantee long-term price stability.
• **Control Shift Risk**: The condition for the election of the Reporting Person and his designees to the Board of Directors could lead to a change in corporate governance and strategic direction.

Future Outlook

The company anticipates a subsequent closing for additional preferred shares and requires stockholder approval for several significant corporate actions, including an increase in authorized ordinary shares, a reverse stock split, and changes to the Board of Directors, to enable the conversion of the preferred shares.

Industry Context

StockSavvy.ai notes that biotech companies, especially those in early or growth stages like Mainz Biomed N.V., frequently rely on capital raises to fund research, development, and operational expenses. The structure of this raise, involving preferred shares with complex conversion terms and conditions like a reverse stock split, is often seen in companies facing challenges with their share price or needing significant capital without immediate common stock dilution. The requirement for a reverse stock split suggests potential Nasdaq listing compliance issues, a common concern for smaller cap companies.

Comparison to Industry Standards

• The capital raise of $6 million is a moderate amount for a biotech company, comparable to early-stage funding rounds for clinical trials or product development. For instance, smaller biotechs like OncoSec Medical Inc. or Soligenix, Inc. have raised similar amounts through preferred stock or convertible notes to fund specific pipeline advancements.
• The conditions for conversion, particularly the need for a reverse stock split and a massive increase in authorized shares, are not standard for healthy, growing companies. This structure is more akin to distressed financing or a strategic move to maintain listing compliance, similar to actions taken by companies like Aeterna Zentaris Inc. or Sio Gene Therapies Inc. when facing low share prices.
• The proposed increase in authorized shares to 900,000,000 and the high conversion ratio (up to 225 ordinary shares per preferred share) indicate a potential for extreme dilution, which significantly exceeds typical industry benchmarks for non-distressed capital raises.

Management Changes

Corporate Governance

Related Party Transactions

• David E. Lazar, a Director and 10% owner of Mainz Biomed N.V., is the reporting person and the counterparty in the securities purchase agreement for the acquisition of preferred shares.

Stakeholder Impact

• **Shareholders**: Potential for significant dilution upon conversion of preferred shares and the impact of a reverse stock split. The requirement for stockholder approval gives them a say in these significant changes.
• **Company**: Receives a crucial capital injection of $3 million immediately, with another $3 million contingent, which can fund operations. However, it comes with significant governance changes and potential future dilution.
• **Board of Directors**: Potential change in composition with the election of David E. Lazar and his designees.

Next Steps

• Obtain Stockholder Approval for: increasing authorized ordinary shares to at least 900,000,000; conversion of all Preferred Shares into ordinary shares in compliance with Nasdaq rules; a reverse stock split; and election of David E. Lazar and his designees to the Company's Board of Directors.
• Subsequent closing for the acquisition of 1,000,000 Series D Preferred Shares and 1,000,000 Series E Preferred Shares.

Key Dates

Recommendation

While the capital injection provides necessary funding, the complex terms, including the contingent conversion, the requirement for a reverse stock split, and the potential for substantial dilution, introduce significant uncertainty and risk. The stock is likely to experience volatility as the market digests these conditions and awaits stockholder approval. Investors should hold to monitor the outcome of the stockholder vote and the subsequent impact on the company's capital structure and share price before making further investment decisions.

Keywords

Mainz Biomed, MYNZ, David E. Lazar, Preferred Shares, Capital Raise, SEC Form 4, Beneficial Ownership, Stockholder Approval, Reverse Stock Split, Dilution, Corporate Governance, Nasdaq Compliance